(1S,2R,3R,5R)-3-(hydroxymethyl)-5-[7-[[(1R,2S)-2-phenylcyclopropyl]amino]-5-propylsulfanyltriazolo[4,5-d]pyrimidin-3-yl]cyclopentane-1,2-diol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并嘧啶类
• 英文名称: (1S,2R,3R,5R)-3-(hydroxymethyl)-5-[7-[[(1R,2S)-2-phenylcyclopropyl]amino]-5-propylsulfanyltriazolo[4,5-d]pyrimidin-3-yl]cyclopentane-1,2-diol
• 化学式: C₂₂H₂₈N₆O₃S
• 分子量: 456.569
• InChiKey: BFPCQWHCVRJEKL-GJWPJNNNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  32
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  155
• 氢给体数：
  4
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  在 三氟乙酸 作用下， 反应 2.0h， 生成 (1S,2R,3R,5R)-3-(hydroxymethyl)-5-[7-[[(1R,2S)-2-phenylcyclopropyl]amino]-5-propylsulfanyltriazolo[4,5-d]pyrimidin-3-yl]cyclopentane-1,2-diol 、
  参考文献：
  名称：

  From ATP to AZD6140: The discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis

  摘要：

  Starting from adenosine triphosphate (ATP), the identification of a novel series of P2Y(12) receptor antagonists and exploitation of their SAR is described. Modifications of the acidic side chain and the purine core and investigation of hydrophobic substituents led to a series of neutral molecules. The leading compound, 17 (AZD6140), is currently in a large phase III clinical trial for the treatment of acute coronary syndromes and prevention of thromboembolic clinical sequelae. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.07.057

文献信息

• From ATP to AZD6140: The discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis
  作者：Brian Springthorpe、Andrew Bailey、Patrick Barton、Timothy N. Birkinshaw、Roger V. Bonnert、Roger C. Brown、David Chapman、John Dixon、Simon D. Guile、Robert G. Humphries、Simon F. Hunt、Francis Ince、Anthony H. Ingall、Ian P. Kirk、Paul D. Leeson、Paul Leff、Richard J. Lewis、Barrie P. Martin、Dermot F. McGinnity、Michael P. Mortimore、Stuart W. Paine、Garry Pairaudeau、Anil Patel、Aaron J. Rigby、Robert J. Riley、Barry J. Teobald、Wendy Tomlinson、Peter J.H. Webborn、Paul A. Willis

  DOI：10.1016/j.bmcl.2007.07.057

  日期：2007.11

  Starting from adenosine triphosphate (ATP), the identification of a novel series of P2Y(12) receptor antagonists and exploitation of their SAR is described. Modifications of the acidic side chain and the purine core and investigation of hydrophobic substituents led to a series of neutral molecules. The leading compound, 17 (AZD6140), is currently in a large phase III clinical trial for the treatment of acute coronary syndromes and prevention of thromboembolic clinical sequelae. (c) 2007 Elsevier Ltd. All rights reserved.